^
    Back
    Association details:
    Biomarker:FLT3‐ITD
    Cancer:Acute Myelogenous Leukemia
    Drug:luxeptinib (CG-806) (BTK inhibitor, FLT3 inhibitor, Myeloid kinome inhibitor, Lymphoid kinome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    2767 A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

    Published date:
    11/03/2022
    Excerpt:
    As of July 8, 2022, luxeptinib is well tolerated at dose levels of 450, 600, 750, and 900 mg BID over multiple cycles without evidence of having reached the MTD. Luxeptinib in heavily pretreated relapsed FLT3-ITD AML patients has shown anti-tumor activity including a durable, MRD negative CR.
    DOI:
    https://doi.org/10.1182/blood-2022-167759
    Trial ID:
    NCT04477291